Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYRO3 | Q06418 | 2/20 | 0.53 |
| ▸ | JAK2 | O60674 | 18/20 | 0.52 |
| ▸ | JAK1 | P23458 | 10/20 | 0.52 |
| ▸ | AXL | P30530 | 1/20 | 0.51 |
| ▸ | MERTK | Q12866 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9947531 | 0.99 | TYRO3 (0.52) | TYRO3JAK2JAK1AXLMERTK | |
| SCHEMBL8585439 | 0.94 | TYRO3 (0.51) | TYRO3JAK2JAK1AXLMERTK | |
| SCHEMBL9897071 | 0.93 | TYRO3 (0.62) | TYRO3JAK2JAK1AXLMERTK | |
| SCHEMBL8617863 | 0.92 | TYRO3 (0.62) | TYRO3JAK2JAK1AXLMERTK | |
| SCHEMBL9947526 | 0.91 | JAK2 (0.51) | TYRO3JAK2JAK1AXLMERTK | |
| SCHEMBL8586705 | 0.91 | TYRO3 (0.48) | TYRO3JAK2JAK1AXLMERTK | |
| SCHEMBL9947527 | 0.90 | TYRO3 (0.48) | TYRO3JAK2JAK1AXLMERTK | |
| SCHEMBL9947530 | 0.90 | TYRO3 (0.48) | TYRO3JAK2JAK1AXLMERTK | |
| Trifluoroacetic Acid SCHEMBL9899375 | 0.90 | TYRO3 (0.59) | TYRO3JAK2JAK1AXLMERTK | |
| SCHEMBL9947520 | 0.90 | TYRO3 (0.48) | TYRO3JAK2JAK1AXLMERTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149682-A1 | HETEROCYCLIC-SUBSTITUTED PYRROLOPYRIDINES AND PYRROLOPYRIMIDINES AS JAK INHIBITORS | INCYTE CORPORATION | 2012-06-14 | — | — | US | disclosed |
| WO-2012068440-A1 | HETEROCYCLIC-SUBSTITUTED PYRROLOPYRIDINES AND PYRROLOPYRIMIDINES AS JAK INHIBITORS | INCYTE CORPORATION (US) | 2012-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149682-A1 | HETEROCYCLIC-SUBSTITUTED PYRROLOPYRIDINES AND PYRROLOPYRIMIDINES AS JAK INHIBITORS | JAK2, JAK1, JAK3 | TYRO3 74/4885JAK2 1/4885JAK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.